|
|
|
|
| LEADER |
02842nam a22004335i 4500 |
| 001 |
978-3-319-56197-4 |
| 003 |
DE-He213 |
| 005 |
20170717181551.0 |
| 007 |
cr nn 008mamaa |
| 008 |
170717s2017 gw | s |||| 0|eng d |
| 020 |
|
|
|a 9783319561974
|9 978-3-319-56197-4
|
| 024 |
7 |
|
|a 10.1007/978-3-319-56197-4
|2 doi
|
| 040 |
|
|
|d GrThAP
|
| 050 |
|
4 |
|a RC261-271
|
| 072 |
|
7 |
|a MJCL
|2 bicssc
|
| 072 |
|
7 |
|a MED062000
|2 bisacsh
|
| 082 |
0 |
4 |
|a 614.5999
|2 23
|
| 245 |
1 |
0 |
|a Resistance to Molecular Therapies for Hepatocellular Carcinoma
|h [electronic resource] /
|c edited by Augusto Villanueva.
|
| 264 |
|
1 |
|a Cham :
|b Springer International Publishing :
|b Imprint: Springer,
|c 2017.
|
| 300 |
|
|
|a XIII, 147 p. 16 illus. in color.
|b online resource.
|
| 336 |
|
|
|a text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a computer
|b c
|2 rdamedia
|
| 338 |
|
|
|a online resource
|b cr
|2 rdacarrier
|
| 347 |
|
|
|a text file
|b PDF
|2 rda
|
| 490 |
1 |
|
|a Resistance to Targeted Anti-Cancer Therapeutics,
|x 2196-5501 ;
|v 13
|
| 505 |
0 |
|
|a Tumor Heterogeneity and Resistance to Targeted Therapies in Hepatocellular Carcinoma -- Modulating Immune Responses to Overcome Resistance in Hepatocellular Carcinoma -- Role of Tumor Microenvironment in Hepatocellular Carcinoma Resistance -- Contribution of the Cancer Stem Cell Phenotype to Hepatocellular Carcinoma Resistance -- Clinical and Preclinical Perspectives on Mechanisms of Sorafenib Resistance in Hepatocellular Carcinoma -- Radiological Assessment of Response to Palliative Treatments in Hepatocellular Carcinoma -- Sorafenib and Clinical Patterns of Resistance in hepatocellular carcinoma -- Overcoming Treatment Resistance in Hepatocellular Carcinoma: regorafenib and lessons from other malignancies.
|
| 520 |
|
|
|a This volume evaluates the clinical patterns of resistance to sorafenib, the impact of trial design in the second-line setting and the current gold standard to define radiological resistance; describes the molecular mechanisms responsible for treatment resistance in HCC patients, including components of the immune system and tumor microenvironment; determines the role of the cancer stem cell phenotype in resistance; reviews the experimental models to study resistance; and addresses new approaches to overcome resistance to sorafenib, using successful examples from other malignancies.
|
| 650 |
|
0 |
|a Medicine.
|
| 650 |
|
0 |
|a Cancer research.
|
| 650 |
1 |
4 |
|a Biomedicine.
|
| 650 |
2 |
4 |
|a Cancer Research.
|
| 700 |
1 |
|
|a Villanueva, Augusto.
|e editor.
|
| 710 |
2 |
|
|a SpringerLink (Online service)
|
| 773 |
0 |
|
|t Springer eBooks
|
| 776 |
0 |
8 |
|i Printed edition:
|z 9783319561967
|
| 830 |
|
0 |
|a Resistance to Targeted Anti-Cancer Therapeutics,
|x 2196-5501 ;
|v 13
|
| 856 |
4 |
0 |
|u http://dx.doi.org/10.1007/978-3-319-56197-4
|z Full Text via HEAL-Link
|
| 912 |
|
|
|a ZDB-2-SBL
|
| 950 |
|
|
|a Biomedical and Life Sciences (Springer-11642)
|
